Medifast, Inc. (MED)

From the record

Medifast, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Medifast, Inc.'s 5 filed years say what it did: revenue went from $1.5 billion in fiscal 2021 to $386 million in fiscal 2025, down 29.1% a year; it rose in 1 of 4 years; the deepest fall was 76% from fiscal 2022 to fiscal 2025; net income was positive in 4 of 5 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Medifast, Inc.'s diluted share count shrank about 0.9% a year, and dividends and buybacks returned about 43% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales (2 under scheduled 10b5-1 plans) and 14 purchases of their own stock on the open market in the year to 2026-11-06, buying about $2 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Medifast, Inc. lost about 9 cents for every dollar of shareholders' money, and gross profitability: its products earned about 111 cents per dollar of everything the company owns. Leverage: it owed about 20 cents per dollar of assets, and net share issuance: its share count grew 0.2% over the year (the filed statements).

From the record

Medifast, Inc.'s standing among 42 graded names in its industry family: revenue of $386 million in fiscal 2025 ranks in the bottom 27% by size; a net margin of -4.8% ranks in the bottom 18%; revenue growth of -37.7% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).

From the record

Medifast, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 10 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (bottom 42%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 22%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Medifast, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $89 million against no long-term debt tagged leaves 36% of its assets as net cash, top 1% of its family; cash from operations less capital spending is 0.3% of revenue (bottom 25%); a gross margin of 71.3% (top 4%); research spending of 1.1% of revenue (top 31%) (its annual report).

From the record

Medifast, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -37.7% a year over the last three filed years against -29.1% over all 5, slowing (bottom 20% of its family); the newest year grew -36% (bottom 4%); research spending grew -1.5% a year (bottom 15%); capital spending grew -30.4% a year (bottom 11%) (its annual reports). Medifast, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Medifast, Inc.'s newest year against its own record: revenue of $386 million in fiscal 2025 came in 4.3% above the $370 million its prior three years' pace pointed to (top 29% of its family); net income of $19 million against a prior three-year average of $82 million (bottom 12%); a net margin of -4.8% against 6.2% before (bottom 17%) (its annual reports).